Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1963-1972

  Graefe Mody, E Ulrike ^a   Padula, S ^b   Ring, A ^a   Withopf, B ^a   Dugi, K A ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

BI 1356; DPP 4; DPP IV; Drug interactions; Linagliptin; Metformin

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; DIPEPTIDYL PEPTIDASE IV; LINAGLIPTIN; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; EVALUATION RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PURINES; QUINAZOLINES; YOUNG ADULT;

EID: 67650799130     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903094361     Document Type: Article

References (29)

1. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-aminopiperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (linagliptin), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase 4 inhibitors. J Pharmacol Exp Ther 2008; 325:175-82
2. Hüttner S, Graefe-Mody EU, Ring A, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of linagliptin, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8
3. Langley AK, Suffoletta TJ, Jennings HR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacother 2007;27:1163-80
4. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007;41:51-60
5. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52: 741-50
6. Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu. 2007:13-20
7. FDA Draft Guidance on Drug Interactions. US FDA Center for Biologics Evaluation and Research (CBER), September 2006. Available at: http://www.fda.gov/CbER/gdlns/interactstud.htm [Last accessed 20 May 2009]
8. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
9. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharmaceutical Res 2005;22:255-9
10. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
11. Heise T, Graefe-Mody EU, Hüttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. Published Online: May 19 2009 (DOI: 10.1111/j.1463-1326.2009.01046.x)
12. Brazg L, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93
13. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin treatment in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 2006; 29:2638-43
14. Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22:1939-47
15. Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 2000;50:325-32
16. Barnett A. Potential role of oral DPP-4 inhibitors in the ADA/ EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents. Int J Clin Pract Suppl 2007; 154:12-18
17. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55-72
18. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007;46:787-802
19. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008;30:513-27
20. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30: 499-512
21. Fuchs H, Tillement J-P, Urien S, et al. Concentration-dependent plasma protein binding of the novel DPP-4 inhibitor linagliptin due to saturable binding to its target in plasma. J Pharm Pharmacol (in press)
22. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94
23. Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon like peptide-1. Biochem Biophys Res Commun 2002;291:1302-8
24. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004;324:92-7
25. DeFronza RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagons secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24: 2943-52
26. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007; 56:1475-80
27. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49
28. Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabetic Med 2005;22:654-7
29. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4